NCT02586337 2019-05-21
Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2/3 Unknown
Clinical Trials
6 trialsNCT02586350 2019-05-21
Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2/3 Completed
NCT02461407 2017-12-29
Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2/3 Unknown
NCT02388919 2017-09-18
ALTER0303
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2/3 Completed
NCT02449343 2017-04-25
Study of Anlotinib in Patients With Soft Tissue Sarcoma（STS）(ALTER0203)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2/3 Unknown
NCT02029209 2016-12-16
To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2/3 Unknown